PD-1/PD-L1抑制剂在三阴性乳腺癌免疫治疗中的研究进展

Research progress of PD-1/PD-L1 inhibitors in immunotherapy of triple-negative breast cancer

乳腺癌是我国女性发病率最高的恶性肿瘤,而三阴性乳腺癌是免疫原性最强、恶性程度最高的乳腺癌亚型。在三阴性乳腺癌中,PD-1/PD-L1信号通路与肿瘤的免疫逃逸密切相关,PD-1/PD-L1抑制剂在单药治疗及联合化疗、新辅助化疗、放疗、靶向治疗、肿瘤疫苗等方面均显示出一定优势,然而在临床应用中也存在一些不良反应。随着相关基础研究及临床试验的开展,越来越多的治疗靶点及生物标志物将会被发现,免疫治疗疗效评价体系也会更加完善,最终实现肿瘤“个体化”的精准治疗。

Breast cancer is the malignant tumor with the highest incidence among women in China.While,the triple-negative breast cancer is the subtype of breast cancer with the strongest immunogenicity and the highest degree of malignancy.In triple-negative breast cancer,the PD-1/PD-L1 signaling pathway is closely related to the immune escape mechanism.PD-1/PD-L1 inhibitors have some advantages in monotherapy and combined chemotherapy,neoadjuvant chemotherapy,radiotherapy,targeted therapy,tumor vaccine,etc.However,there are some adverse reactions in clinical application.With the development of related basic research and clinical trials,more and more therapeutic targets and biomarkers will be discovered,and the evaluation system of immunotherapy effect will also be more perfect.The‘individualized’accurate treatment of tumor.